Biomarkers in Transplant Recipients to Improve Outcomes

Launched by UNIVERSITY OF PITTSBURGH · Jul 14, 2010

Keywords

ClinConnect Summary

This clinical trial is looking at how certain proteins found in the bodies of transplant recipients can help us understand how well treatments work for preventing organ rejection. Organ rejection can happen when the body’s immune system attacks the new organ, and understanding these proteins may help doctors find better ways to manage this issue. The study is open to participants of all ages who have received abdominal (like kidneys or livers), thoracic (like hearts or lungs), or bone marrow transplants and are receiving follow-up care at the University of Pittsburgh Medical Center.

To be eligible for this trial, participants or their parents need to be able to read and understand the consent form. Those who join the study will have their protein levels tested and monitored through routine lab tests. This research aims to improve the outcomes for transplant recipients, which means helping them stay healthy and reducing the chances of rejection. If you or a loved one is interested in participating, it could contribute to important discoveries that benefit future transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Recipients of abdominal, thoracic and bone marrow allografts that are receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center.
• • All Ages
• • Subject or parents are able to read and understand the informed consent
• Exclusion Criteria:
• • Subjects and/or their parents who are unable to read and understand informed consent.